EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patent 8,579,865. This new patent is related to a previously issued U.S. patent 8,480,631, and includes additional claims that describe injection devices for the subcutaneous delivery of methotrexate. The expiry date for this patent is 2030. The issuance of this patent further protects the OTREXUP™ injection system by describing the injector and methods of use resulting in methotrexate blood levels bioequivalent to needle and syringe injections. With the addition of this patent, there are now 7 patents listed in the Orange Book related to OTREXUP™.
Help employers find you! Check out all the jobs and post your resume.
